Hay fever, or allergic rhinitis, is an allergic reaction to pollen-producing plants, most commonly ragweed. It’s a common condition, inducing such symptoms as coughing, sneezing, runny nose and eyes, and wheezing. Treatments include avoiding exposure to allergens, over the counter and prescription medications, nasal sprays, and standard immunotherapy or “allergy desensitization”. This story reports on the results of a new study published in the New Enland Journal of Medicine on a new approach to treating hay fever – a ragweed vaccine.
The story adequately describes the design of the current study, rightly pointing out that it was small and preliminary and that the study did not demonstrate effectiveness in an important outcome. The story accurately describes what is known about the harms of the vaccine at this time. However, the story should have mentioned that more research is needed to determine how safe the vaccine is. The story quotes two experts – the author of the current study and an allergy expert with the National Institute of Allergy and Infectious Diseases. The story does mention alternatives, such as medications, nasal sprays and standard immunotherapy.
The story did state that “a commercial product is still years away.” The story also states that further studies could “eventually lead to drug approval by the FDA.” That’s true, but they could also lead to FDA rejection. It’s almost a meaningless line and could have been deleted without losing anything from the story.
The story states that the therapy could cost “thousands of dollars.” However, that’s a broad range and we wish the story had told readers whether that means two or three thousand or ten or twenty. We know it’s an early idea and cost projections are somewhat speculative.
Overall, a well-balanced story.
The story states that the therapy could cost “thousands of dollars,” so we’ll give it the benefit of the doubt. However, that’s a broad range and we wish the story had told readers whether that means two or three thousand or ten or twenty. We know it’s an early idea and cost projections are somewhat speculative.
The story discussed benefits of the vaccine in relative terms only. It quotes a researcher saying “The magnitude of the effects are really impressive,” but never really quantified the magnitude of the effects.
The story accurately describes what is known about the harms of the vaccine at this time. The story should have mentioned that more research is needed to determine how safe the vaccine is.
The story adequately describes the design of the current study, rightly pointing out that it was small and preliminary and did not demonstrate effectiveness of the vaccine in an important outcome.
The story does not appear to engage in disease mongering.
The story quotes two experts – the author of the current study and an allergy expert at the National Institute of Allergy and Infectious Diseases. The latter is not exactly an impartial source since NIAID helped fund the study, but he did caution about the signficance of the study, “limited by its small size and the vaccine’s failure to affect the primary immune system response it was designed to look for.”
The story does mention alternatives, such as medications, nasal sprays and allergen immunotherapy.
The story did state that “a commercial product is still years away.” The story also states that further studies could “eventually lead to drug approval by the FDA.” That’s true, but they could also lead to FDA rejection. It’s almost a meaningless line and could have been deleted without losing anything from the story.
The story clearly states that vaccination is a new approach for treating hay fever.
There is no way to know if the story relied on a press release as the sole source of information, although much of the information apparently came from the principal investigator at Johns Hopkins and from the National Institute of Allergy and Infectious Diseases, which was one of the funders of the study.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like